Broncholytin vial 125 ml # 44303
Код АТХ: R05FA
5 g syrup contain: 5.75 mg glaucine hydrobromide; 4.60 mg ephedrine hydrochloride.
Combined treatment of diseases affecting respiratory system, accompanied by cough and catarrhal changes of various intensity: acute catarrhal inflammations of the upper respiratory tract, acute and chronic bronchitis and tracheobronchitis; bronchial asthma; pneumonia; bronchiectasis; whooping cough.
Dosage and administration:
In adults: 2 scoops (10 ml), 3-4 times daily.
In children from 3 to 10 years: 1 scoop (5 ml), 3 times daily
In children over 10 years: 2 scoops (10 g), 3 times daily.
Due to Ephedrinun hydrochloricum content, the product is contraindicated in stenocardia; severe organic diseases of the heart; thyrotoxicosis; hypertension; pheochromocytoma; glaucoma; prostate hypertrophy with urine retention. Broncholytin is contraindicated in patients with hypersensitivity to the product. Broncholytin is not suitable for patients with inborn intolerance to fructose, glucose/ galactose syndrome of malabsorption or sucrose-isomaltose deficiency.
Broncholytin may be used together with antibiotics, chemotherapeutics, antipyretics, and vitamins.
Concomitant administration with digitalis glycosides or general anesthetics may provoke cardiac arrhythmia. Similar effects may be observed in interaction with ergotamine, methylergometrine or oxytocin. MAO-inhibitors potentiate the pressure effect of Ephedrinum hydrochloricum (there is a risk of hypertensive reactions). Reserpine reduces the pressure effect of Ephedrinum hydrochloricum. The interaction of Ephedrinum hydrochloricum with other sympathomimetics may enhance their effects.
Due to Ephedrinum hydrochloricum content in the syrup, 15-30 minutes after administration mild and transient adverse reactions may appear as tremor, palpitations, mild agitation, and sweating; somnolence in children. Possible are reactions of hypersensitivity (urticaria, dermatitis, bronchospasm), due to parahydroxybenzoates content in the product. In patients with prostatic hypertrophy, urine retention may be observed. In patients with cardiovascular system diseases, rhythm and conductivity disturbances and arterial hypertension are possible.
Vial containing 125 g syrup.
Manufactured by Sopharma AD: www.sopharma.com
Copyright © 2016-2017 BPG Ltd/Biogenic Stimulants, Inc. All rights reserved.EV SSL